What are the most important transactions and litigations that you have been involved in during the last two years?

Our biotechnology research subsidiary made substantial progress developing new compounds for treating cancer and for improving the quality of life for cancer patients. Our medical device development subsidiary obtained patent protection, completed clinical trials, and obtained CE mark approval for a device improving venous access for chemotherapy patients and others with conditions making venous access difficult. We successfully concluded litigation in the US concerning the performance of a clinical trial necessary for obtaining FDA approval.

What impact did the pandemic have on the pharmaceutical and medical technology industries in Switzerland?

One of the main impacts was that scientific research and clinical trials were delayed because medical personnel were needed to respond to the pandemic.

What “legal tech” products do you currently utilise, and do you foresee implementing more of these in the future?

Cloud technology is the foundation of our IT architecture. Our adoption of this technology before the Covid-19 pandemic allowed us to transition from office to working from home without any adverse impact. Our automated contract management system, automated grant management system, and integrated CRM system provide an efficient, resilient, and easy-to-use way of accessing, managing, and protecting corporate data.

We also rolled out multiple automated monitoring systems protect our brand, IP rights, and reputation, as well as legal research systems and databases provide efficient and up to date access to laws and regulations. To protect our data and systems, we also have automated cyber security monitoring software.

We are continuously seeking ways to improve by using legal technology.